Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Phase 1 Clinical Study to Determine the Maximum Tolerated Dose/Maximum Feasible Dose, Safety,& Efficacy of Single Dose Rhenium-186 NanoLiposome (186RNL) Administered Via Intraventricular Catheter for Leptomeningeal Metastases

NCT05034497 is registered in ClinicalTrials.gov with Plus Therapeutics as lead sponsor.

NCT NCT05034497
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05034497 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Phase 1 Clinical Study to Determine the Maximum Tolerated Dose/Maximum Feasible Dose, Safety,& Efficacy of Single Dose Rhenium-186 NanoLiposome (186RNL) Administered Via Intraventricular Catheter for Leptomeningeal Metastases
Lead sponsor
Plus Therapeutics
Phase
Phase 1
Overall status
Active, not recruiting
Start date
December 6, 2021
Completion date
June 30, 2026
Enrollment
18 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

leptomeningeal metastasis